Platinum Industries Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

Qualified audit opinionExceptional itemRevenue growth above 20%Results View source PDF Explain this filing

PLATIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.8%Reaction day

₹229.95

prior close

₹227.55

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.5%+6.3% vs market

Specialty Chemicals peers, median of 86sector-1.6%+6.5% vs sector

On the reaction day the stock moved 6.3 pts more than Nifty Microcap 250 and 6.5 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

-0.7

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.8-1.5+6.3-1.6+6.5

Next day

+1.4-2.2+3.6-3.0+4.4

+0.1-1.2+1.3-2.5+2.6

+0.2-0.9+1.2-1.7+2.0

+1.0-2.3+3.3-3.1+4.1

-1.5-2.5+0.9-3.0+1.5

-1.3-3.6+2.3-3.6+2.3

15d

-8.7-10.4+1.7-10.4+1.6

-10.9-11.3+0.5-11.3+0.4

-7.3-3.6-3.7-5.5-1.8

+4.8+3.9+0.9+0.8+4.0

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 86Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Platinum Industries reported Q3 FY26 (Dec 31, 2025) results with standalone revenue from operations up ~30.8% YoY at ₹1,026.20 million and consolidated revenue up ~12% at ₹1,046.68 million. Standalone profit after tax grew ~18.4% YoY to ₹129.26 million, while consolidated PAT rose ~7% to ₹123.28 million for the quarter. However, for the nine-month period, standalone PAT fell ~11.6% YoY to ₹375.78 million and consolidated PAT dropped ~16.9% to ₹363.87 million, partly weighed by an exceptional loss of ₹5.17 million related to a July 2025 fire at subsidiary Platinum Polymers & Additives. The statutory auditor (PKF Sridhar & Santhanam LLP) issued a 'Qualified Conclusion' on both standalone and consolidated results, flagging uncertainty over recognition of an insurance receivable of ₹98.19 million. The board also approved incorporation of a new subsidiary, 'Rivadu Lifesciences Private Limited', to enter the pharmaceuticals and life-sciences segment with an initial capital of ₹25 lakh.

Likely market impact

Strong quarterly topline growth is positive, but the qualified auditor opinion and ongoing uncertainty over the ₹98.19 million insurance claim are near-term concerns for shareholders. The move into pharma/life-sciences through a new subsidiary signals diversification, which could be a long-term positive but adds execution risk.